Literature DB >> 3402466

Comparison of acute haemodynamic effects of dopexamine hydrochloride, dobutamine and sodium nitroprusside in chronic heart failure.

G Baumann1, M Gutting, C Pfafferott, K Ningel, G Klein.   

Abstract

Dopexamine hydrochloride (Dopacard) is a new synthetic catecholamine compound, which possesses potent beta 2-adrenergic and DA1-dopaminergic agonistic properties. It is free of alpha-adrenergic activity, has no beta 1-adrenergic activity and is less potent at DA2-dopaminergic receptors than dopamine. In the present study the acute haemodynamic effects of dopexamine hydrochloride were compared to those of dobutamine and nitroprusside in 12 patients with idiopathic congestive cardiomyopathy in an open crossover study. With dopexamine hydrochloride, there were dose-dependent increases from control in cardiac output and stroke volume, decreases in blood pressure, right and left atrial pressure, systemic vascular resistance and pulmonary vascular resistance and little change in heart rate. Similar effects were seen with nitroprusside, apart from a marked increase in heart rate, and with dobutamine, except that systolic aortic blood pressure increased and there was no change in diastolic or mean pressure or pulmonary artery systolic pressure. In general, dopexamine hydrochloride produced effects between those produced by the other two treatments. This suggests that dopexamine with its combined vasodilator and inotropic action has a desirable cardiovascular profile with advantages over the beta 1-receptor agonist dobutamine and the pure vasodilator sodium nitroprusside.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3402466     DOI: 10.1093/oxfordjournals.eurheartj.a062536

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  4 in total

Review 1.  Dopexamine in congestive heart failure: how do the pharmacological activities translate into the clinical situation?

Authors:  T Meinertz; H Drexler; H Just
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

2.  Intravenous dopexamine in the treatment of acute congestive heart failure: results of a multicenter, double-blind, placebo-controlled withdrawal study.

Authors:  H Asanoi; S Sasayama; T Sakurai; J D Lee; M Kinoshita; T Ishimura; J Yoshikawa; K Mitsudo; H Sato; S Morioka
Journal:  Cardiovasc Drugs Ther       Date:  1995-12       Impact factor: 3.727

3.  Circulatory and diuretic effects of dopexamine infusion in low-birth-weight infants with respiratory failure.

Authors:  P Kawczynski; A Piotrowski
Journal:  Intensive Care Med       Date:  1996-01       Impact factor: 17.440

Review 4.  Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency.

Authors:  A Fitton; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.